Neoadjuvant chemotherapy and prognosis of pregnancy-associated breast cancer: Atime-trends study of the korean breast cancer registry database

Korean Breast Cancer Society

Research output: Contribution to journalArticle

Abstract

Purpose: Pregnancy-associated breast cancer (PABC) is rare, and its cause and prognosis are not well known. Additionally, treatment is limited with respect to the risk to the fetus. The purpose of this study was to investigate the characteristics and treatment trends of PABC and the survival rate according to the treatment. Methods: In the Korean Breast Cancer Society Registry database, women younger than 50 years and who were diagnosed with breast cancer from 1996 to 2015 were included. PABC was defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Results: We examined 411 patients with PABC and 83,381 patients with non-PABC. Over time, the proportions of patients undergoing breast-conserving surgery and sentinel lymph node biopsy increased, and neoadjuvant chemotherapy and radiation therapy administration rates also increased. In the past, the overall survival of patients with PABC was poorer than that of patients with non-PABC, but there was no difference in overall survival rates in more recent years. There was no difference in overall survival rates between patients who received neoadjuvant chemotherapy (hazard ratio [HR], 1.28; 95% confidence interval [CI], 0.66–2.49; p= 0.459), but PABC conferred poorer prognosis than non-PABC in patients receiving adjuvant chemotherapy (HR, 1.63; 95% CI, 1.27–2.08; p< 0.001). Conclusion: There was no difference in the prognosis between patients with PABC and those with non-PABC receiving neoadjuvant chemotherapy. The increase in neoadjuvant chemotherapy according to current treatment guidelines is expected to improve the survival rate of patients with PABC.

Original languageEnglish
Pages (from-to)425-432
Number of pages8
JournalJournal of Breast Cancer
Volume21
Issue number4
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Registries
Databases
Breast Neoplasms
Drug Therapy
Pregnancy
Survival Rate
Confidence Intervals
Sentinel Lymph Node Biopsy
Neoadjuvant Therapy
Segmental Mastectomy
Therapeutics
Adjuvant Chemotherapy
Fetus
Radiotherapy
Guidelines

Keywords

  • Breast neoplasms
  • Drug therapy
  • Pregnancy
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neoadjuvant chemotherapy and prognosis of pregnancy-associated breast cancer : Atime-trends study of the korean breast cancer registry database. / Korean Breast Cancer Society.

In: Journal of Breast Cancer, Vol. 21, No. 4, 01.12.2018, p. 425-432.

Research output: Contribution to journalArticle

@article{20c5b23002bf44f9be06107d3839f196,
title = "Neoadjuvant chemotherapy and prognosis of pregnancy-associated breast cancer: Atime-trends study of the korean breast cancer registry database",
abstract = "Purpose: Pregnancy-associated breast cancer (PABC) is rare, and its cause and prognosis are not well known. Additionally, treatment is limited with respect to the risk to the fetus. The purpose of this study was to investigate the characteristics and treatment trends of PABC and the survival rate according to the treatment. Methods: In the Korean Breast Cancer Society Registry database, women younger than 50 years and who were diagnosed with breast cancer from 1996 to 2015 were included. PABC was defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Results: We examined 411 patients with PABC and 83,381 patients with non-PABC. Over time, the proportions of patients undergoing breast-conserving surgery and sentinel lymph node biopsy increased, and neoadjuvant chemotherapy and radiation therapy administration rates also increased. In the past, the overall survival of patients with PABC was poorer than that of patients with non-PABC, but there was no difference in overall survival rates in more recent years. There was no difference in overall survival rates between patients who received neoadjuvant chemotherapy (hazard ratio [HR], 1.28; 95{\%} confidence interval [CI], 0.66–2.49; p= 0.459), but PABC conferred poorer prognosis than non-PABC in patients receiving adjuvant chemotherapy (HR, 1.63; 95{\%} CI, 1.27–2.08; p< 0.001). Conclusion: There was no difference in the prognosis between patients with PABC and those with non-PABC receiving neoadjuvant chemotherapy. The increase in neoadjuvant chemotherapy according to current treatment guidelines is expected to improve the survival rate of patients with PABC.",
keywords = "Breast neoplasms, Drug therapy, Pregnancy, Prognosis",
author = "{Korean Breast Cancer Society} and Bae, {Soo Youn} and Kim, {Ku Sang} and Kim, {Jeong Soo} and Lee, {Sae Byul} and Park, {Byeong Woo} and Lee, {Seok Won} and Lee, {Hyouk Jin} and Kim, {Hong Kyu} and You, {Ji Young} and Jung, {Seung Pil}",
year = "2018",
month = "12",
day = "1",
doi = "10.4048/jbc.2018.21.e58",
language = "English",
volume = "21",
pages = "425--432",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy and prognosis of pregnancy-associated breast cancer

T2 - Atime-trends study of the korean breast cancer registry database

AU - Korean Breast Cancer Society

AU - Bae, Soo Youn

AU - Kim, Ku Sang

AU - Kim, Jeong Soo

AU - Lee, Sae Byul

AU - Park, Byeong Woo

AU - Lee, Seok Won

AU - Lee, Hyouk Jin

AU - Kim, Hong Kyu

AU - You, Ji Young

AU - Jung, Seung Pil

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose: Pregnancy-associated breast cancer (PABC) is rare, and its cause and prognosis are not well known. Additionally, treatment is limited with respect to the risk to the fetus. The purpose of this study was to investigate the characteristics and treatment trends of PABC and the survival rate according to the treatment. Methods: In the Korean Breast Cancer Society Registry database, women younger than 50 years and who were diagnosed with breast cancer from 1996 to 2015 were included. PABC was defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Results: We examined 411 patients with PABC and 83,381 patients with non-PABC. Over time, the proportions of patients undergoing breast-conserving surgery and sentinel lymph node biopsy increased, and neoadjuvant chemotherapy and radiation therapy administration rates also increased. In the past, the overall survival of patients with PABC was poorer than that of patients with non-PABC, but there was no difference in overall survival rates in more recent years. There was no difference in overall survival rates between patients who received neoadjuvant chemotherapy (hazard ratio [HR], 1.28; 95% confidence interval [CI], 0.66–2.49; p= 0.459), but PABC conferred poorer prognosis than non-PABC in patients receiving adjuvant chemotherapy (HR, 1.63; 95% CI, 1.27–2.08; p< 0.001). Conclusion: There was no difference in the prognosis between patients with PABC and those with non-PABC receiving neoadjuvant chemotherapy. The increase in neoadjuvant chemotherapy according to current treatment guidelines is expected to improve the survival rate of patients with PABC.

AB - Purpose: Pregnancy-associated breast cancer (PABC) is rare, and its cause and prognosis are not well known. Additionally, treatment is limited with respect to the risk to the fetus. The purpose of this study was to investigate the characteristics and treatment trends of PABC and the survival rate according to the treatment. Methods: In the Korean Breast Cancer Society Registry database, women younger than 50 years and who were diagnosed with breast cancer from 1996 to 2015 were included. PABC was defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Results: We examined 411 patients with PABC and 83,381 patients with non-PABC. Over time, the proportions of patients undergoing breast-conserving surgery and sentinel lymph node biopsy increased, and neoadjuvant chemotherapy and radiation therapy administration rates also increased. In the past, the overall survival of patients with PABC was poorer than that of patients with non-PABC, but there was no difference in overall survival rates in more recent years. There was no difference in overall survival rates between patients who received neoadjuvant chemotherapy (hazard ratio [HR], 1.28; 95% confidence interval [CI], 0.66–2.49; p= 0.459), but PABC conferred poorer prognosis than non-PABC in patients receiving adjuvant chemotherapy (HR, 1.63; 95% CI, 1.27–2.08; p< 0.001). Conclusion: There was no difference in the prognosis between patients with PABC and those with non-PABC receiving neoadjuvant chemotherapy. The increase in neoadjuvant chemotherapy according to current treatment guidelines is expected to improve the survival rate of patients with PABC.

KW - Breast neoplasms

KW - Drug therapy

KW - Pregnancy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85059288955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059288955&partnerID=8YFLogxK

U2 - 10.4048/jbc.2018.21.e58

DO - 10.4048/jbc.2018.21.e58

M3 - Article

AN - SCOPUS:85059288955

VL - 21

SP - 425

EP - 432

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 4

ER -